Radiotherapy and Chemoradiotherapy

  • Xingchu NiEmail author
  • Kun (Kim) Huang


Neoadjuvant radiation therapy or chemoradiotherapy followed by surgery has the potential to improve patient survival by reducing the risk of locoregional and distant metastasis of gastric cardiac cancer in both thoracic and abdominal organs. Because of the limited case number in prior clinical trials on the efficacy of radiation or chemoradiotherapy for gastric cardiac cancer, multicenter studies with large case numbers are urgently needed to establish an optimal therapy protocol for this cancer.


Gastric cancer Stomach Cancer Gastric cardia Radiation therapy Chemoradiotherapy 


  1. 1.
    Siewert JR, Holscher AH, Becker K, et al. [Cardia cancer: attempt at a therapeutically relevant classification]. Chirurg. 1987;58(1):25–32.Google Scholar
  2. 2.
    Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662–9.CrossRefPubMedGoogle Scholar
  3. 3.
    van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRefPubMedGoogle Scholar
  4. 4.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Chou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.CrossRefGoogle Scholar
  6. 6.
    Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)—report on 370 patients. Int J Radiat Oncol Biol Phys. 1998;42(5):929–34.CrossRefPubMedGoogle Scholar
  8. 8.
    Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Cancer Genome Atlas Research Network, Analysis Working Group, Asan University, BC Cancer Agency, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75.CrossRefGoogle Scholar
  11. 11.
    Klevebro F, Johnsen G, Johnson E, et al. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: a randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Eur J Surg Oncol. 2015;41(7):920–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Badgwell B, Ajani J, Blum M, et al. Postoperative morbidity and mortality rates are not increased for patients with gastric and gastroesophageal cancer who undergo preoperative chemoradiation therapy. Ann Surg Oncol. 2016;23(1):156–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Fiorica F, Cartei F, Enea M, et al. The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev. 2007;33(8):729–40.CrossRefPubMedGoogle Scholar
  14. 14.
    Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zhao Q, Li Y, Wang J, et al. Concurrent neoadjuvant chemoradiotherapy for siewert II and III adenocarcinoma at gastroesophageal junction. Am J Med Sci. 2015;349(6):472–6.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Leong T, Smithers BM, Michael M, et al. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer. 2015;15:532.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 2013;5:CD008107.Google Scholar
  19. 19.
    Fu T, Bu ZD, Li ZY, et al. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer. 2015;15:322.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Macdonald JS, Benedetti J, Smalley S, et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol. 2009;27(15_suppl):4515.Google Scholar
  21. 21.
    Coburn NG, Govindarajan A, Law CH, et al. Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients. Ann Surg Oncol. 2008;15(2):500–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Le Chevalier T, Smith FP, Harter WK, et al. Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma. Semin Oncol. 1985;12(1):46–53.PubMedGoogle Scholar
  25. 25.
    Gunderson LL, Hoskins RB, Cohen AC, et al. Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys. 1983;9(7):965–75.CrossRefPubMedGoogle Scholar
  26. 26.
    Kole TP, Aghayere O, Kwah J, et al. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1580–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Wu AJ, Bosch WR, Chang DT, et al. Expert consensus contouring guidelines for intensity modulated radiation therapy in esophageal and gastroesophageal junction cancer. Int J Radiat Oncol Biol Phys. 2015;92(4):911–20.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Wo JY, Yoon SS, Guimaraes AR, et al. Gastric lymph node contouring atlas: a tool to aid in clinical target volume definition in 3-dimensional treatment planning for gastric cancer. Pract Radiat Oncol. 2013;3(1):e11–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Meier I, Merkel S, Papadopoulos T, et al. Adenocarcinoma of the esophagogastric junction: the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition. Int J Radiat Oncol Biol Phys. 2008;70(5):1408–17.CrossRefPubMedGoogle Scholar
  30. 30.
    Smalley SR, Gunderson L, Tepper J, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys. 2002;52(2):283–93.CrossRefPubMedGoogle Scholar
  31. 31.
    Wieland P, Dobler B, Mai S, et al. IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int J Radiat Oncol Biol Phys. 2004;59(4):1236–44.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of RadiotherapyAffiliated Changzhou No 2 People’s Hospital, Nanjing Medical UniversityChangzhouPeople’s Republic of China
  2. 2.Department of Radiation OncologyHarvard Medical School, Boston University School of Medicine, VA Boston Healthcare SystemJamaica PlainUSA

Personalised recommendations